Recent Analysts’ Ratings Updates for REGENXBIO (RGNX)

A number of research firms have changed their ratings and price targets for REGENXBIO (NASDAQ: RGNX):

• 2/15/2025 – REGENXBIO was downgraded by analysts at StockNews.com from a “hold” rating to a “sell” rating.
• 2/11/2025 – REGENXBIO was downgraded by analysts at The Goldman Sachs Group, Inc. from a “buy” rating to a “neutral” rating. They now have a $14.00 price target on the stock, down previously from $38.00.
• 2/7/2025 – REGENXBIO is now covered by analysts at Raymond James. They set an “outperform” rating and a $27.00 price target on the stock.
• 2/7/2025 – REGENXBIO was upgraded by analysts at StockNews.com from a “sell” rating to a “hold” rating.
• 2/6/2025 – REGENXBIO was upgraded by analysts at Raymond James to a “moderate buy” rating.
• 1/23/2025 – REGENXBIO was downgraded by analysts at StockNews.com from a “hold” rating to a “sell” rating.
• 1/21/2025 – REGENXBIO had its “outperform” rating reaffirmed by analysts at Royal Bank of Canada. They now have a $30.00 price target on the stock.
• 1/15/2025 – REGENXBIO had its “buy” rating reaffirmed by analysts at HC Wainwright. They now have a $36.00 price target on the stock.

REGENXBIO Price Performance

Shares of NASDAQ:RGNX opened at $7.27 on Monday. The company’s 50-day moving average price is $7.70 and its two-hundred day moving average price is $9.59. REGENXBIO Inc. has a one year low of $6.56 and a one year high of $28.80. The stock has a market capitalization of $360.16 million, a PE ratio of -1.45 and a beta of 1.29.

Institutional Investors Weigh In On REGENXBIO

A number of institutional investors and hedge funds have recently modified their holdings of RGNX. Hennion & Walsh Asset Management Inc. raised its holdings in shares of REGENXBIO by 13.1% in the 3rd quarter. Hennion & Walsh Asset Management Inc. now owns 151,715 shares of the biotechnology company’s stock valued at $1,591,000 after purchasing an additional 17,525 shares during the period. China Universal Asset Management Co. Ltd. grew its stake in REGENXBIO by 64.3% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 9,506 shares of the biotechnology company’s stock valued at $100,000 after buying an additional 3,720 shares during the last quarter. Harbor Capital Advisors Inc. grew its stake in REGENXBIO by 48.5% in the 3rd quarter. Harbor Capital Advisors Inc. now owns 36,082 shares of the biotechnology company’s stock valued at $379,000 after buying an additional 11,784 shares during the last quarter. Sigma Planning Corp grew its stake in REGENXBIO by 17.5% in the 3rd quarter. Sigma Planning Corp now owns 38,210 shares of the biotechnology company’s stock valued at $401,000 after buying an additional 5,701 shares during the last quarter. Finally, Connor Clark & Lunn Investment Management Ltd. acquired a new position in REGENXBIO in the 3rd quarter valued at about $643,000. 88.08% of the stock is owned by institutional investors.

REGENXBIO Inc, a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company’s products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy.